Imperial College London

Pixelgen Technologies Announces Peer-Review Publication on Molecular Pixelation Technology in Nature Methods

Retrieved on: 
水曜日, 5月 8, 2024
Royal Society Te Apārangi, Karolinska Institute, Cancer, Protein, MPX, Cell, Pixelation, Proteomics, MD, AOCS, Doctor of Philosophy, Research, Imperial College London, DNA, PBMC, Light, Spatial analysis, Microscopy, Messenger, Paper, B cell, Immobilization, NK, Royal institute, Monocyte, Flow cytometry, Vaccine

STOCKHOLM, May 8, 2024 /PRNewswire/ -- Pixelgen Technologies, a leader in spatial proteomics for single cells, announced today that researchers from Pixelgen, the Karolinska Institute, Imperial College of London, and the Royal Institute of Technology in Sweden have demonstrated a ground-breaking sequencing-based method for identifying the relative locations of highly-multiplexed immunologically relevant proteins in single cells, in a peer-reviewed article published in Nature Methods. The Molecular Pixelation (MPX) technology used in the study is the first to demonstrate spatial proteomics of single cells without light, enabling multiplexing, throughput, and spatial resolution in 3D for proteomics-level single cell research.

Key Points: 
  • The Molecular Pixelation (MPX) technology used in the study is the first to demonstrate spatial proteomics of single cells without light, enabling multiplexing, throughput, and spatial resolution in 3D for proteomics-level single cell research.
  • The study, titled "Molecular Pixelation: Spatial Proteomics of single cells by sequencing," illustrates the ability of a DNA-barcode-based strategy to identify and visualize in 3D the spatial protein organization of immune cell receptors.
  • How immune cell surface receptors are organized relative to each other, and their behavior control many of a cell's vital functions.
  • Researchers have traditionally studied spatial surface protein organization with microscopy, using fluorophore-labeled antibodies on immobilized samples or with flow cytometry.

New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer

Retrieved on: 
金曜日, 5月 3, 2024
Biotechnology, Health, Clinical Trials, Health Technology, Oncology, Breast cancer, Neoplasm, Patient, Cancer, NTRA, HER2, Woman, MRD, RFS, Recurrence, MD, Doctor of Philosophy, OS, JCO, Genetic testing, Imperial College London, DNA, Plasma, Central Statistics Office (India), Medical imaging

The study evaluated a total of 1,136 prospectively collected and banked plasma samples from 156 early-stage breast cancer patients enrolled in the multi-site Exploratory Breast Lead Interval Study (EBLIS).

Key Points: 
  • The study evaluated a total of 1,136 prospectively collected and banked plasma samples from 156 early-stage breast cancer patients enrolled in the multi-site Exploratory Breast Lead Interval Study (EBLIS).
  • Patients were followed for up to 12 years after surgery and adjuvant chemotherapy, with blood samples collected semi-annually and then analyzed using Signatera.
  • In a multivariate analysis, ctDNA status was the most significant factor associated with RFS and OS.
  • “The findings also bolster the evidence for long-term monitoring of high-risk breast cancer patients, who often face late recurrences.”

Pixelgen Technologies Appoints Mostafa Ronaghi to Scientific Advisory Board

Retrieved on: 
火曜日, 4月 30, 2024
Stanford University, Membrane, Karolinska Institute, Genomics, Mostafa Ronaghi, Pyrosequencing, Pixelation, Clear Labs, Proteome, Imperial College London, Culture, GRAIL, Drug development, Management

STOCKHOLM, April 30, 2024 /PRNewswire/ -- Pixelgen Technologies announced today the appointment of Mostafa Ronaghi, Ph.D., to its Scientific Advisory Board.

Key Points: 
  • STOCKHOLM, April 30, 2024 /PRNewswire/ -- Pixelgen Technologies announced today the appointment of Mostafa Ronaghi, Ph.D., to its Scientific Advisory Board.
  • "Mostafa is a recognized life sciences visionary leader, with deep expertise in genomics and a tested entrepreneurial spirit," said Pixelgen CEO Simon Fredriksson.
  • "These attributes align well with Pixelgen's mission and culture, and we are honored to have him on our board.
  • "I'm thrilled to join Pixelgen's Scientific Advisory Board and look forward to working with the company's impressive team to continue developing Molecular Pixelation," Ronaghi said.

Great Eagle Gold Corp. Announces New Board Member and Financing

Retrieved on: 
金曜日, 4月 12, 2024
UNICEF, Funding, Warrant, Imperial College London, Legislation, Acquisition, UNICEF UK, Social responsibility, Canadian Securities Exchange, The, Electronic, Allied health professions, Security (finance)

Chris Hansen, Chairman of Great Eagle Gold, expressed his enthusiasm, stating, "It is with great pleasure that we welcome Michael to our esteemed team.

Key Points: 
  • Chris Hansen, Chairman of Great Eagle Gold, expressed his enthusiasm, stating, "It is with great pleasure that we welcome Michael to our esteemed team.
  • Each whole Warrant will be exercisable for an additional common share of Great Eagle at $0.75 per share for twenty-four months following the closing of the Financing.
  • Great Eagle plans to pay finder's fees of up to 10% in cash and warrants in connection with the Financing.
  • During the past several months, Great Eagle has been diligently reviewing dozens of potential acquisition candidates.

Hyster-Yale Group provides students with real-world AI experience in 2024 Kellogg Design Challenge

Retrieved on: 
木曜日, 5月 2, 2024
UCLA, University, Berea College, SVKM's NMIMS, East Carolina University, AI, Management, Research, Student, Business, Lexmark, PwC, Imperial College London, Intelligence, Cornell University, Carnegie Mellon University, Senior, IDEO, Kellogg School, Lockheed Martin, MBA, University of Chicago, Q&A

GREENVILLE, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Representatives from Hyster-Yale Group joined Northwestern faculty from the Kellogg School of Management and Segal Institute for Design Innovation and innovation industry leaders like IDEO, PwC and IA Collaborative to facilitate the 2024 Kellogg Design Challenge, the largest business design case competition across MBA programs globally.

Key Points: 
  • GREENVILLE, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Representatives from Hyster-Yale Group joined Northwestern faculty from the Kellogg School of Management and Segal Institute for Design Innovation and innovation industry leaders like IDEO, PwC and IA Collaborative to facilitate the 2024 Kellogg Design Challenge, the largest business design case competition across MBA programs globally.
  • “As we pursue that mission, the Kellogg Design Challenge is an outstanding opportunity to tap into some of the brightest young minds.
  • “We want to thank the Kellogg Design Challenge team, and the graduate students from reputed universities for their outstanding engagement in making the Kellogg Design Challenge an incredible success,” says Dr. Gopi Samayajula, Senior Vice President of Global Product Development, Hyster-Yale.
  • In addition to the Kellogg Design Challenge, Hyster-Yale has several longstanding collaborations with academic and career development programs across the country.

Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts

Retrieved on: 
木曜日, 4月 25, 2024
Genetics, CMO, Doctor of Philosophy, Boston, Development, Novartis, Pfizer, Operating partner, Functional genomics, CSO, Genome, Associate, Drug discovery, SAB, AbbVie, Baxalta, EVP, GSK plc, Bristol Myers Squibb, GSK, Baylor College of Medicine, University, Harvard Medical School, Therapy, Biotechnology, Inflammation, Hospital, NIH, Michigan State University, Respiratory Medicine, Imperial College London, IPO, Rockefeller University, Spatial, MPH, Genomics, Atlas Venture, Merck Serono, Genentech, University of Birmingham, Senior, Society, Acquisition, Discovery, Sanofi, Baylor University

New Non-Executive Director of the Board, John Davis MD, MPH, MS, brings extensive and varied experience as a physician-scientist, drug developer and biotechnology executive.

Key Points: 
  • New Non-Executive Director of the Board, John Davis MD, MPH, MS, brings extensive and varied experience as a physician-scientist, drug developer and biotechnology executive.
  • The SAB is chaired by Prof. Jim Hughes, Scientific Founder and Non-Executive Director of Nucleome Therapeutics.
  • Dr Russell Greig, Non-Executive Chair of the Nucleome’s Board, said: “We are delighted to have appointed such esteemed experts to the Nucleome team.
  • Steve’s multifaceted background, spanning academia, industry and leadership roles, positions him as a key contributor to Nucleome’s Scientific Advisory Board.

Rigetti and Oxford Instruments Announce Successful Completion of Innovate UK Project to Launch One of the First UK-Based Quantum Computers

Retrieved on: 
火曜日, 4月 16, 2024
Cloud, University, Humidity, Standard Chartered, Amazon Web Services, Area studies, Machine learning, Data science, Computer, Quantum, Research, QCS, Imperial College London, Algorithm, Rigetti Computing, QSL, Innovate UK, Standard, AWS, Oxford Instruments, UKRI, Quantum computing, Microscope

The consortium was backed by funding from the UK government’s Quantum Technologies Challenge, led by UK Research & Innovation (UKRI).

Key Points: 
  • The consortium was backed by funding from the UK government’s Quantum Technologies Challenge, led by UK Research & Innovation (UKRI).
  • The system was hosted at Oxford Instruments’ Tubney Woods facility using Oxford Instruments’ ProteoxLX dilution refrigerator, and was supported by Oxford Instruments’ state-of-the-art infrastructure and expert cryogenics support.
  • The UK has become a world leader in quantum computing technologies, and we are excited to continue to contribute to its quantum computing capabilities.
  • My thanks to this outstanding team of ‘quantrepreneurs’ – led by Rigetti UK Limited – who have made the vision a reality.”

Owlstone Medical Secures $6.5 Million to Support Development of Breath-based Diagnostics for Infectious Disease

Retrieved on: 
木曜日, 4月 25, 2024
Biotechnology, Pharmaceutical, AIDS, Health, Medical Devices, Infectious Diseases, Philanthropy, Foundation, VOC, University, Organic compound, Atlas, University of Oxford, Volatile organic compound, Partnership, Disease, Imperial College London, Viral load, Bill, Melinda French Gates, Medicine, Infection, Diagnosis, HIV, Biomarker, TB, Tuberculosis, Medical imaging

The funding is comprised of a $5 million equity investment to advance Owlstone’s Breath Biopsy platform and $1.5 million in grant funding to develop breath-based diagnostics and identify breath biomarkers for tuberculosis (TB) and HIV.

Key Points: 
  • The funding is comprised of a $5 million equity investment to advance Owlstone’s Breath Biopsy platform and $1.5 million in grant funding to develop breath-based diagnostics and identify breath biomarkers for tuberculosis (TB) and HIV.
  • Owlstone, with support from the foundation, is interested in developing new cost-effective detection technologies for volatile organic compounds (VOCs) that could serve as markers of diseases that disproportionately affect the developing world.
  • Billy Boyle, co-founder and CEO at Owlstone Medical, said: “Early diagnosis is a critical determinant of health outcomes.
  • This investment by the Gates Foundation is testament to how Owlstone is uniquely positioned to transform infectious disease diagnosis through our Breath Biopsy platform.

Zero Energy Devices Markets and Technology Report 2024-2044: Essential Guide to this Large New ZED Opportunity - How to Create a $1 Billion ZED Business - ResearchAndMarkets.com

Retrieved on: 
火曜日, 4月 23, 2024
Technology, Other Technology, Conclusion, Internet, Executive, Chapter Six, RFID, SWOT, Chapter Ten, Chapter Three, Heart, Communication, Electricity, Ultra, Research, Transducer, EAS, Life, Rest, Imperial College London, Attention, Electronics, Chapter Seven, Wireless, WPT, Vibration, Chapter Nine, RIS, ZED, Movement, Toxicity, Chapter Five, Chapter Two, Telecommunications, IOT, Chapter Eight, Recycling, Chapter Four

The "Zero Energy Devices ZED: Self-Powered and Backscatter-Powered Electronics and Electrics Markets, Technology 2024-2044" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Zero Energy Devices ZED: Self-Powered and Backscatter-Powered Electronics and Electrics Markets, Technology 2024-2044" report has been added to ResearchAndMarkets.com's offering.
  • You can create a billion-dollar business from making the next ZED materials or devices as detailed in this commercially-oriented 408-page report.
  • The primary author has created several successful high-tech businesses, so the report is realistic, including warnings concerning dead ends and over-promising.
  • At this stage you will realise that many zero energy devices without storage have been presented throughout the report.

Sofinnova Partners Appoints Two New Partners Strengthening Team of Next Generation Investors

Retrieved on: 
月曜日, 4月 22, 2024
Professional Services, Health, Other Professional Services, Environment, Sustainability, Other Health, Finance, Baxter, Sofinnova, Biotechnology, Chemical industry, Doctor of Philosophy, Growth, Imperial College London, Myocardial infarction, Heart failure, Renewable energy

These promotions underscore Sofinnova's dedication to developing talent from within its own ranks and commitment to driving impactful change in the sector.

Key Points: 
  • These promotions underscore Sofinnova's dedication to developing talent from within its own ranks and commitment to driving impactful change in the sector.
  • Gkelou joined Sofinnova as an Analyst in the Capital Strategy in 2017 after working as an immunology scientist at Danone Nutricia.
  • As a Partner in the Capital Strategy, Gkelou will play a key role in investing in the next generation of early-stage biotech companies.
  • "I am honored to have been part of the Industrial Biotechnology team since its early days," Baxter said.